Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal\'s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases.

High prevalence of diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and autoimmune diseases is likely to play a key role in driving the market growth for anti-inflammatory peptides. According to the World Psoriasis Day consortium, worldwide nearly 125 million people are affected with psoriasis, approximately 2% to 3% of the global population. The World Health Organization (WHO) predicts the median multiple sclerosis prevalence approximately 30 per 100,000 individuals. Crohn’s disease (CD) and ulcerative colitis (UC) are two major inflammatory bowel diseases. Crohn’s disease has been observed to be more prevalent in urban areas than rural. Statistics released by the World Health Organization (WHO) indicates that the CD incidence rate in Asian and South American countries is less than 1 per 10,000 people, 1–3 per 100,000 in southern Europe, South Africa, 16 per 100,000 in New Zealand and Australia and 7 per 100,000 in the U.S. Such high prevalence and incidence rate of aforementioned diseases indicates promising market for anti-inflammatory peptides.

There are many companies that are striving to develop anti-Inflammatory peptides. One of them is San Francisco Bay Area based start-up named Rogne Biosciences that plans to develop world’s first topical anti-Inflammatory peptide product, derived from naturally occurring body protein to treat patients suffering from psoriasis. Rogne Biosciences has obtained a licensing agreement from Isis Innovation, the commercialization company of University of Oxford, to develop anti-inflammatory peptides. In February 2013, Phylogica, a leading peptide drug discovery company, and Bio-Link Australia signed an agreement to commercialize anti-inflammatory Phylomer peptides for pharmaceutical use. This commercialization effort of both companies will be funded by a grant of USD 20,000 from the Western Australian government under the Innovation Vouchers Program (IVP). A research is going on to study the cationic antimicrobial peptides effectiveness against clinically relevant microorganisms such as propionibacterium acnes. The study demonstrates that in addition to the antimicrobial activity, cationic antimicrobial peptides also exhibit anti-inflammatory effect.

Globally, North America, Europe, Asia-Pacific and Rest of the World (RoW) are the four major regions for which anti-inflammatory peptides market has been analyzed. In North America, U.S. and Canada are the major countries. Well established healthcare infrastructure and insurance landscape of these two countries have led North America dominating the anti-inflammatory peptides market. According to the National Psoriasis Foundation, approximately 7.5 million people (2.2% of the population) in the U.S. are living with psoriasis. As per the National Multiple Sclerosis Society, 400,000 individuals estimated to have multiple sclerosis in the U.S. The high prevalence of psoriasis and multiple sclerosis is also responsible for North America’s leading position in the global anti-inflammatory peptides market. In the European region, the EU-5 countries (Germany, France, U.K., Spain and Italy) represent the most potential markets. However, during the forecast period from 2014 to 2020, Eastern European region are expected to witness high growth rate than western region. The growing economy of countries such as India and China, and continuously improving healthcare scenario of Asia-Pacific region are the key factors driving the market growth in the region.

Some of the major players contributing to the global anti-inflammatory peptides market include Abbvie, Digna Biotech, Araim Pharmaceuticals, Inc., F4 Pharma, Merck Serono, Rogne Bioscience, Novartis AG and Mylan Pharmaceuticals.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Anti Inflammatory Peptides Market

Pre Book